Drug Trial Radar · NCT04706429
The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Dec 1, 2020
Primary completion
Apr 30, 2024
Study completion Jul 30, 2024
Sponsor
- Lead sponsor
- Manchester University NHS Foundation TrustGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- National Institute for Health Research, United Kingdom; University of Manchester; University of Liverpool; Univar BV; University of Oxford
- First posted
- Jan 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study has been designed to test whether a drug called trientine dihydrochloride (also called Cufence) reduces heart muscle thickening, improves exercise capacity, improves heart function and reduces abnormal heart rhythms in patients with hypertrophic cardiomyopathy (HCM). The study is also assessing how trientine works in HCM. Participants will be prescribed either trientine or placebo, for a period of 12 months.
Conditions
- Hypertrophic Cardiomyopathy
Interventions
TrientineDrug
Trientine dihydrochloride is a white to pale yellow crystalline hygroscopic powder.
PlaceboDrug
Placebo capsule, manufactured with the exact components of the trientine capsules, without the active ingredient / investigational medicinal product.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Left ventricular mass indexed to body surface area (LVMi)Time frame: 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
NHS Grampian
Aberdeen, United Kingdom
University Hospitals of Leicester NHS Foundation Trust
Leicester, United Kingdom
Liverpool Heart and Chester Hospital NHS Foundation Trust
Liverpool, United Kingdom
Royal Brompton and Harefield NHS Foundation Trust
London, United Kingdom
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Northumbria Healthcare NHS Foundation Trust
North Shields, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.